TNSN06025A1 - Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant - Google Patents

Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant

Info

Publication number
TNSN06025A1
TNSN06025A1 TNP2006000025A TNSN06025A TNSN06025A1 TN SN06025 A1 TNSN06025 A1 TN SN06025A1 TN P2006000025 A TNP2006000025 A TN P2006000025A TN SN06025 A TNSN06025 A TN SN06025A TN SN06025 A1 TNSN06025 A1 TN SN06025A1
Authority
TN
Tunisia
Prior art keywords
les
dérivés
oligosaccharides
mélanges
contenant
Prior art date
Application number
TNP2006000025A
Other languages
English (en)
French (fr)
Inventor
Christian Viskov
Volker Laux
Pierre Mourier
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of TNSN06025A1 publication Critical patent/TNSN06025A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2006000025A 2003-07-24 2006-01-23 Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant TNSN06025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0309041A FR2857971B1 (fr) 2003-07-24 2003-07-24 Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
PCT/FR2004/001943 WO2005010051A2 (fr) 2003-07-24 2004-07-22 Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
TNSN06025A1 true TNSN06025A1 (en) 2007-10-03

Family

ID=33561051

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000025A TNSN06025A1 (en) 2003-07-24 2006-01-23 Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant

Country Status (39)

Country Link
EP (1) EP1651677B1 (enExample)
JP (1) JP4865552B2 (enExample)
KR (1) KR101125517B1 (enExample)
CN (1) CN1852926B (enExample)
AR (1) AR045917A1 (enExample)
AT (1) ATE487741T1 (enExample)
AU (1) AU2004259111B2 (enExample)
BR (1) BRPI0412850A (enExample)
CA (1) CA2533555A1 (enExample)
CR (1) CR8201A (enExample)
CY (1) CY1111165T1 (enExample)
DE (1) DE602004030015D1 (enExample)
DK (1) DK1651677T3 (enExample)
EC (1) ECSP066305A (enExample)
ES (1) ES2355827T3 (enExample)
FR (1) FR2857971B1 (enExample)
GT (1) GT200400145A (enExample)
HN (1) HN2004000250A (enExample)
IL (1) IL173206A (enExample)
MA (1) MA27928A1 (enExample)
ME (1) MEP11608A (enExample)
MX (1) MXPA06000336A (enExample)
MY (1) MY136769A (enExample)
NO (1) NO20060821L (enExample)
NZ (1) NZ544717A (enExample)
OA (1) OA13197A (enExample)
PA (1) PA8606801A1 (enExample)
PE (1) PE20050246A1 (enExample)
PL (1) PL1651677T3 (enExample)
PT (1) PT1651677E (enExample)
RS (1) RS20060044A (enExample)
RU (1) RU2346005C2 (enExample)
SI (1) SI1651677T1 (enExample)
TN (1) TNSN06025A1 (enExample)
TW (1) TWI369208B (enExample)
UA (1) UA89356C2 (enExample)
UY (1) UY28435A1 (enExample)
WO (1) WO2005010051A2 (enExample)
ZA (1) ZA200600657B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589145B2 (en) 2004-04-15 2009-09-15 Exxonmobil Chemical Patents Inc. Syndiotactic rich polyolefins
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
CN101711771B (zh) * 2008-10-07 2015-12-09 上海喜恩医药科技发展有限公司 一种肝素衍生的多糖混合物及其制法和药物组合物
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
WO2012072799A1 (en) 2010-12-02 2012-06-07 Aventis Pharma S.A. New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample
CN102558392A (zh) * 2010-12-14 2012-07-11 王芃 一种高抗FXa、低抗FIIa低分子肝素钠的制备方法
CN102816255B (zh) * 2011-06-10 2015-11-25 王芃 一种超低分子肝素钠的制备方法
EP2980103B1 (en) 2013-03-26 2020-11-04 Jiuzhitang Co., Ltd. Low molecular weight glycosaminoglycan derivative, pharmaceutical composition thereof, preparation method therefor and use thereof
CN103864959A (zh) * 2014-04-03 2014-06-18 中国药科大学 一种肝素十二糖抗动脉粥样硬化的用途
RU2639574C2 (ru) * 2016-05-23 2017-12-21 Алексей Георгиевич Александров Способ получения низкомолекулярного гепарина

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
FR2504928A1 (fr) * 1981-04-29 1982-11-05 Choay Sa Oligosaccharides a chaines courtes possedant des proprietes biologiques, leur preparation et leurs applications en tant que medicaments
FR2669932B1 (fr) * 1990-12-03 1994-07-01 Sanofi Sa Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent.
IT1284143B1 (it) * 1996-09-06 1998-05-08 Istituto Scient Di Chimica E B Eparansolfati semi-sintetici ad elevata attivita' antimetastica e ridotto rischio emorragico
AU7753898A (en) * 1997-06-06 1998-12-21 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
FR2807043B1 (fr) * 2000-03-28 2002-11-22 Aventis Pharma Sa Composition pharmaceutique contenant des oligosaccharides, les nouveaux oligosaccharides et leur preparation
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FR2811992B1 (fr) * 2000-07-21 2003-07-04 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
CA2458852A1 (en) * 2001-08-28 2003-03-06 Leo Pharma A/S Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
FR2845686B1 (fr) * 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
EP1651677A2 (fr) 2006-05-03
MXPA06000336A (es) 2006-03-30
TW200522970A (en) 2005-07-16
KR20060059974A (ko) 2006-06-02
JP2006528614A (ja) 2006-12-21
IL173206A (en) 2010-11-30
PE20050246A1 (es) 2005-06-02
NZ544717A (en) 2009-09-25
SI1651677T1 (sl) 2011-03-31
GT200400145A (es) 2005-03-16
AU2004259111A1 (en) 2005-02-03
AR045917A1 (es) 2005-11-16
RU2006105384A (ru) 2007-09-10
UA89356C2 (ru) 2010-01-25
CN1852926A (zh) 2006-10-25
ES2355827T3 (es) 2011-03-31
CY1111165T1 (el) 2015-06-11
DE602004030015D1 (de) 2010-12-23
CN1852926B (zh) 2010-05-12
WO2005010051A3 (fr) 2005-06-16
PT1651677E (pt) 2011-02-08
ATE487741T1 (de) 2010-11-15
AU2004259111B2 (en) 2009-06-11
KR101125517B1 (ko) 2012-03-23
ECSP066305A (es) 2006-07-28
IL173206A0 (en) 2006-06-11
ZA200600657B (en) 2007-05-30
PA8606801A1 (es) 2005-02-04
DK1651677T3 (da) 2011-02-28
RU2346005C2 (ru) 2009-02-10
CR8201A (es) 2006-09-22
MEP11608A (en) 2010-06-10
JP4865552B2 (ja) 2012-02-01
BRPI0412850A (pt) 2006-10-03
WO2005010051A2 (fr) 2005-02-03
PL1651677T3 (pl) 2011-04-29
TWI369208B (en) 2012-08-01
FR2857971B1 (fr) 2005-08-26
CA2533555A1 (fr) 2005-02-03
NO20060821L (no) 2006-04-20
HK1094806A1 (zh) 2007-04-13
RS20060044A (sr) 2008-06-05
EP1651677B1 (fr) 2010-11-10
MA27928A1 (fr) 2006-06-01
UY28435A1 (es) 2005-02-28
HN2004000250A (es) 2006-06-29
OA13197A (fr) 2006-12-13
MY136769A (en) 2008-11-28
FR2857971A1 (fr) 2005-01-28

Similar Documents

Publication Publication Date Title
TNSN06025A1 (en) Mélanges d'oligosaccharides dérivés d'heparine, leur préparation et les compositions pharmaceutiques les contenant
BG104780A (en) Inhibitors of phospholipase enzymes
EA200300580A1 (ru) Соединения лактама
WO2005016235A3 (en) Combined use of impdh inhibitors with toll-like receptor agonists
MA30359B1 (fr) Composition pharmaceutique a liberation prolongee sur la base d'un systeme de liberation comprenant un polymere soluble dans l'acide et un polymere dependant du ph
WO1998038984A3 (en) Formulations for hydrophobic pharmaceutical agents
YU38801A (sh) Azabicikloalkani kao modulatori ccr5
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
EP1649849A3 (fr) Compositions pour le traitement de la maladie de parkinson contentant un antagoniste du récepteur CB1 et un produit qui active la neurotransmission dompaminerque dans le cerveau
MY157377A (en) Ophthalmic composition
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
AU2002305099A1 (en) Fatty alcohol drug conjugates
HRP20020330B1 (enExample)
PL351593A1 (en) Substantially oil−free cyclosporin compositions
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
DZ3166A1 (fr) Dérivés de la purine, leur procédé de préparation,et compositions pharmaceutiques les contenant.
YU67900A (sh) Sukcinamidni inhibitori interleukin-1beta konvertujućeg enzima
PL1608344T3 (pl) Doustne formulacje kladrybiny
MY137965A (en) Semi-solid formulations for the oral administrations of taxoids
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2003000199A3 (en) Ilt3 and ilt4-related compositions and methods
WO2002056010A3 (en) Methods for the treatment of ibs
AU4925200A (en) Oral composition containing perlite
MXPA04001976A (es) Hormona de crecimiento humano modificada.